Influenza Vaccine Formulation
The recommended influenza vaccine composition for New Zealand in 2010 is:
- A(H1N1): an A/California/7/2009 (H1N1)-like strain, 15 mcg HA per dose
- A(H3N2): an A/Perth/16/2009 (H3N2)-like strain, 15 mcg HA per dose
- B: a B/Brisbane/60/2008-like strain, 15 mcg HA per dose
The following viruses are recommended as suitable vaccine strains:
- A/California/7/2009 (H1N1) (NYMC X-179A, NYMC X-181, NYMC X-181A, NIBRG-121, NIBRG-121xp)
- A/Perth/16/2009 (H3N2)-like virus
- B/Brisbane/60/2008
This recommendation is based on the outcome of:
- The meeting of the Australian Influenza Vaccine Committee, with a New Zealand representative, to consult on the influenza vaccine composition for 2010 (held on 2nd October 2009),
- Information on international surveillance by the World Health Organisation (WHO) Global Influenza Surveillance Network,
- Recent data from Australia, New Zealand, Argentina and South Africa on epidemiology and strain characterisation, and
- The recommendations of the WHO annual consultation on the composition of 2010 influenza vaccine for the Southern Hemisphere